Global Glutamate Antagonist Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

According to our (Global Info Research) latest study, the global Glutamate Antagonist market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.

Glutamate Antagonists work by inhibiting the activity of glutamate receptors in the brain. These receptors are broadly classified into two main subtypes: N-methyl-D-aspartate (NMDA) and 3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors.

Glutamate antagonists are being investigated as potential treatments for various neurological and psychiatric disorders, including epilepsy, depression, anxiety disorders, neuropathic pain, and neurodegenerative diseases like Alzheimer"s and Parkinson"s. Some glutamate antagonists have been approved for use in treating epilepsy, particularly drug-resistant forms of the condition.

This report is a detailed and comprehensive analysis for global Glutamate Antagonist market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Glutamate Antagonist market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global Glutamate Antagonist market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global Glutamate Antagonist market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global Glutamate Antagonist market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Glutamate Antagonist

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Glutamate Antagonist market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Artemis Neuroscience, VistaGen Therapeutics, Rottapharm Madaus, Amorsa Therapeutics, Newron Pharmaceuticals, Purdue Biopharma, Relmada Therapeutics, BioCrea GmbH, Cerecor Inc., NeurOp Inc., etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Glutamate Antagonist market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Ionic
Non Ionic

Market segment by Application
Hospitals
Clinics
Laboratory
Others

Major players covered
Artemis Neuroscience
VistaGen Therapeutics
Rottapharm Madaus
Amorsa Therapeutics
Newron Pharmaceuticals
Purdue Biopharma
Relmada Therapeutics
BioCrea GmbH
Cerecor Inc.
NeurOp Inc.
UCB SA
Novartis AG
Luc Therapeutics Inc.
Evotec AG

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Glutamate Antagonist product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Glutamate Antagonist, with price, sales quantity, revenue, and global market share of Glutamate Antagonist from 2020 to 2025.

Chapter 3, the Glutamate Antagonist competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Glutamate Antagonist breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Glutamate Antagonist market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Glutamate Antagonist.

Chapter 14 and 15, to describe Glutamate Antagonist sales channel, distributors, customers, research findings and conclusion.